Prospective clinical trials to investigate clinical and molecular biomarkers

被引:11
|
作者
Auvin, Stehane [1 ,2 ]
Walker, Lauren [3 ]
Gallentine, William [4 ]
Jozwiak, Sergiusz [5 ]
Tombini, Mario [6 ]
Sills, Graeme J. [3 ]
机构
[1] Robert Debre Univ Hosp, AP HP, Pediat Neurol Dept, Paris, France
[2] Robert Debre Univ Hosp, AP HP, INSERM U1141, Paris, France
[3] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[4] Duke Univ, Med Ctr, Dept Pediat Neurol, Durham, NC USA
[5] Med Univ Warsaw, Dept Child Neurol, Warsaw, Poland
[6] Campus Biomed Univ, Dept Med, Neurol Unit, Neurophysiol,Neurobiol, Rome, Italy
基金
英国医学研究理事会;
关键词
Biomarkers; Epilepsy; HMGB1; IL-1; beta; Inflammation; Prospective study; TEMPORAL-LOBE EPILEPSY; EXPERIMENTAL FEBRILE SEIZURES; C-11; DEUTERIUM-DEPRENYL; BRAIN INFLAMMATION; RAT MODEL; MICROGLIAL ACTIVATION; TRANSLOCATOR PROTEIN; EMISSION-TOMOGRAPHY; FOCAL EPILEPSY; EPILEPTOGENESIS;
D O I
10.1111/epi.13782
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Among clinical studies, randomized studies as well as well-designed observational studies are providing the highest quality data. In addition, these studies represent a good opportunity to examine biomarkers of ictogenesis and epileptogenesis. To date, no validated molecular or cellular biomarker exists for any aspect of epilepsy. We provide an overview of the inflammatory biomarkers under investigation in prospective clinical studies in epilepsy: proinflammatory cytokines in prolonged febrile seizure; High Mobility Group Box 1 (HMGB1) as a prognosis biomarker in epilepsy and the interaction between inflammation and metabolism, in particular, iron metabolism, in epilepsy. The designs of the European Union EPISTOP project following prospectively patients with tuberous sclerosis from birth to the start of the epilepsy and of the Standard and New Antiepileptic Drugs-II study illustrate how such studies can be used to find new inflammatory biomarkers of ictogenesis and epileptogenesis. If we want to bridge the current gap between having numerous biomarker candidates from preclinical studies and their selective use in clinical practice, we need to explore multiple biologic systems, not just including inflammation. In addition, it is crucial that those involved in the design and support of relevant clinical studies recognize this gap and act accordingly, and in the interests of improving the diagnosis and prognosis for epilepsy.
引用
收藏
页码:20 / 26
页数:7
相关论文
共 50 条
  • [1] Molecular Imaging Biomarkers for Oncology Clinical Trials
    Mankoff, David A.
    Pryma, Daniel A.
    Clark, Amy S.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (04) : 525 - 528
  • [2] CLINICAL TRIALS BASED ON BIOMARKERS
    Rosell, R.
    Moran, T.
    [J]. LUNG CANCER, 2009, 64 : S4 - S4
  • [3] Biomarkers and clinical trials in ALS
    Genge, Angela
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [4] Integrating biomarkers in clinical trials
    Buyse, Marc
    Michiels, Stefan
    Sargent, Daniel J.
    Grothey, Axel
    Matheson, Alastair
    de Gramont, Aimery
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (02) : 171 - 182
  • [5] Assessing clinical utility and clinical validity of biomarkers in clinical trials
    Caldas, C.
    [J]. BREAST, 2023, 68 : S3 - S3
  • [6] Clinical trials to investigate daily or frequent hemodialysis
    不详
    [J]. GERIATRIC NURSING, 2004, 25 (02) : 70 - 71
  • [7] The Autism Biomarkers Consortium for Clinical Trials: EEG and ET Biomarkers for Use in Clinical Trials With Children With ASD
    Webb, Sara
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 63 - 64
  • [8] Prospective registration of clinical trials
    Wille-Jorgensen, P
    Gluud, C
    [J]. COLORECTAL DISEASE, 2006, 8 (01) : 1 - 1
  • [9] Prospective registration of clinical trials
    Askie, Lisa
    Ghersi, Davina
    Simes, John
    [J]. AUSTRALIAN JOURNAL OF PHYSIOTHERAPY, 2006, 52 (04): : 237 - 239
  • [10] Using biomarkers in clinical trials in ophthalmology
    Beuerman, R.
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95